论文部分内容阅读
目的依折麦布联合辛伐他汀对慢性肾炎伴高血压患者心肾保护效果的长期随访研究。方法选取郑州市第十人民医院2010年4月至2011年4月80例慢性肾炎伴高血压患者为研究对象,将患者抽签随机分为观察组与对照组,每组40例。对照组给予辛伐他汀治疗,观察组在对照组的基础上另行依折麦布干预,随访1年,比较两组甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)等血脂水平,血尿素氮、肌酐等肾功能指标,收缩压、舒张压,心血管事件发生率及不良反应发生率。结果观察组治疗后TC、TG、LDL-C水平低于对照组,HDL-C水平高于对照组,有统计学意义(P<0.05)。观察组血尿素氮(9.24±5.13)mmol/L、肌酐(212.69±68.53)μmol/L均低于对照组,有统计学意义(P<0.05)。观察组收缩压、舒张压均低于对照组,有统计学意义(P<0.05)。观察组心血管事件发生率22.50%低于对照组45.00%,有统计学意义(P<0.05)。两组不良反应发生率比较无统计学意义(P>0.05)。结论依折麦布联合辛伐他汀治疗慢性肾炎伴高血压,可有效调节患者血脂水平,降低血压,改善患者肾功能,远期治疗效果较好,安全性高,具有较好的临床应用价值。
Aim Long-term follow-up study of cardioprotective effect of ezetimibe and simvastatin on patients with chronic nephritis and essential hypertension. Methods Eighty patients with chronic nephritis with hypertension were selected from the 10th People’s Hospital of Zhengzhou City from April 2010 to April 2011. The patients were randomly divided into observation group and control group, with 40 patients in each group. The control group was treated with simvastatin. The observation group was treated with ezine for a period of one year. The levels of TG, TC, HDL C) and low-density lipoprotein cholesterol (LDL-C), blood urea nitrogen, creatinine and other renal function parameters, systolic blood pressure, diastolic blood pressure, cardiovascular events and the incidence of adverse reactions. Results The levels of TC, TG and LDL-C in the observation group were lower than those in the control group, and the levels of HDL-C in the observation group were higher than those in the control group (P <0.05). Blood urea nitrogen (9.24 ± 5.13) mmol / L and creatinine (212.69 ± 68.53) μmol / L in the observation group were significantly lower than those in the control group (P <0.05). Systolic blood pressure and diastolic blood pressure were lower in the observation group than in the control group, with statistical significance (P <0.05). The incidence of cardiovascular events in observation group was lower than 22.50% in control group (45.00%), with statistical significance (P <0.05). The incidence of adverse reactions in the two groups was not statistically significant (P> 0.05). Conclusion Ezetimibe combined with simvastatin in the treatment of chronic nephritis with hypertension can effectively regulate the level of blood lipids, lower blood pressure and improve renal function in patients with long-term treatment is better, high safety, and has good clinical value.